Christine Fox
Known title: EVP, Head of U.S. CommercialCIK: 0001998173
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 21,258 | $751K | 4/30/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 17,819 | — | 3/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 7,924 | $251K | 3/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,461 | — | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 9,098 | $295K | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 28,229 | $700K | 11/20/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 63,492 | — | 11/20/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 30,000 | $753K | 11/14/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 2,147 | $34K | 3/5/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,461 | — | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 4,034 | $63K | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 63,492 | — | 11/20/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 19,388 | $327K | 11/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.